Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Not Confirmed
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Not Confirmed
Not Confirmed
11-13 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Industry Trade Show
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Industry Trade Show
Not Confirmed
11-13 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities
11 Jul 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/07/11/2911999/0/en/Eloxx-Pharmaceuticals-Provides-Pipeline-and-Financing-Updates.html
16 Apr 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/04/16/2863493/0/en/Eloxx-Pharmaceuticals-Provides-ELX-02-and-ZKN-013-Program-Updates.html
13 Mar 2024
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2024/03/13/2845650/0/en/Almirall-and-Eloxx-Pharmaceuticals-Enter-into-Exclusive-Agreement-to-license-ZKN-013-for-rare-dermatological-diseases.html
13 Nov 2023
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2023/11/13/2779493/0/en/Eloxx-Pharmaceuticals-Reports-Third-Quarter-2023-Financial-and-Operating-Results-and-Provides-Business-Update.html
https://www.globenewswire.com//news-release/2023/10/09/2756643/0/en/Eloxx-Pharmaceuticals-Reports-Additional-Confirmation-that-All-Nonsense-Mutation-Alport-Syndrome-Patients-Treated-with-ELX-02-in-Phase-2-Study-had-Improvement-in-Kidney-Morphology-.html
19 Sep 2023
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2023/09/19/2745534/0/en/Eloxx-Pharmaceuticals-Announces-2-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html
Details:
ELX-02 (exaluren) is an investigational, advanced synthetic eukaryotic ribosome selective glycoside. It is being evaluated for the treatment of nonsense mutation alport syndrome.
Lead Product(s): Exaluren Sulfate
Therapeutic Area: Genetic Disease Brand Name: ELX-02
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2024
Lead Product(s) : Exaluren Sulfate
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
Details : ELX-02 (exaluren) is an investigational, advanced synthetic eukaryotic ribosome selective glycoside. It is being evaluated for the treatment of nonsense mutation alport syndrome.
Brand Name : ELX-02
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 16, 2024
Details:
Almirall obtains exclusive global rights to develop and commercialize ZKN-013, Eloxx’s lead TURBO-ZM based molecule, for rare dermatological and other diseases associated with nonsense mutations.
Lead Product(s): ZKN-013
Therapeutic Area: Genetic Disease Brand Name: ZKN-013
Study Phase: IND EnablingProduct Type: Small molecule
Sponsor: Almirall
Deal Size: $473.0 million Upfront Cash: $3.0 million
Deal Type: Licensing Agreement March 13, 2024
Lead Product(s) : ZKN-013
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Almirall
Deal Size : $473.0 million
Deal Type : Licensing Agreement
Almirall and Eloxx License ZKN-013 for Rare Dermatological Diseases
Details : Almirall obtains exclusive global rights to develop and commercialize ZKN-013, Eloxx’s lead TURBO-ZM based molecule, for rare dermatological and other diseases associated with nonsense mutations.
Brand Name : ZKN-013
Molecule Type : Small molecule
Upfront Cash : $3.0 million
March 13, 2024
Details:
ELX-02 (exaluren sulfate) is a small molecule drug candidate designed to restore production of full-length functional proteins. It is being developed for the treatment of alport syndrome.
Lead Product(s): ELX-02
Therapeutic Area: Genetic Disease Brand Name: ELX-02
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2023
Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ELX-02 (exaluren sulfate) is a small molecule drug candidate designed to restore production of full-length functional proteins. It is being developed for the treatment of alport syndrome.
Brand Name : ELX-02
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 09, 2023
Details:
The proceeds will advance ELX-02 (exaluren sulfate), being developed for the treatment of Alport syndrome with nonsense mutations and other rare proteinuric kidney diseases, progress the development of ZKN-013 and to fund discovery efforts for the company’s TURBO-ZM™ platform.
Lead Product(s): Exaluren Sulfate
Therapeutic Area: Genetic Disease Brand Name: ELX-02
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: H.C. Wainwright & Co.
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 19, 2023
Lead Product(s) : Exaluren Sulfate
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : H.C. Wainwright & Co.
Deal Size : $2.0 million
Deal Type : Public Offering
Details : The proceeds will advance ELX-02 (exaluren sulfate), being developed for the treatment of Alport syndrome with nonsense mutations and other rare proteinuric kidney diseases, progress the development of ZKN-013 and to fund discovery efforts for the compan...
Brand Name : ELX-02
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 19, 2023
Details:
ELX-02 (exaluren sulfate) is a small molecule drug candidate designed to restore production of full-length functional proteins. It is being developed for the treatment of alport syndrome.
Lead Product(s): Exaluren Sulfate
Therapeutic Area: Genetic Disease Brand Name: ELX-02
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Lead Product(s) : Exaluren Sulfate
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ELX-02 (exaluren sulfate) is a small molecule drug candidate designed to restore production of full-length functional proteins. It is being developed for the treatment of alport syndrome.
Brand Name : ELX-02
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 18, 2023
Details:
ELX-02 (exaluren sulfate) is a small molecule drug candidate designed to restore production of full-length functional proteins. It is being developed for the treatment of alport syndrome.
Lead Product(s): Exaluren Sulfate
Therapeutic Area: Genetic Disease Brand Name: ELX-02
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2023
Lead Product(s) : Exaluren Sulfate
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013
Details : ELX-02 (exaluren sulfate) is a small molecule drug candidate designed to restore production of full-length functional proteins. It is being developed for the treatment of alport syndrome.
Brand Name : ELX-02
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 07, 2023
Details:
ELX-02 (exaluren sulfate) is a small molecule drug candidate designed to restore production of full-length functional proteins. It is being developed for the treatment of alport syndrome.
Lead Product(s): Exaluren Sulfate
Therapeutic Area: Genetic Disease Brand Name: ELX-02
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 14, 2023
Lead Product(s) : Exaluren Sulfate
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ELX-02 (exaluren sulfate) is a small molecule drug candidate designed to restore production of full-length functional proteins. It is being developed for the treatment of alport syndrome.
Brand Name : ELX-02
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 14, 2023
Details:
ELX-02 exaluren) is a small molecule drug candidate designed to restore production of full-length functional proteins. It is being developed for the treatment of CF patients with nonsense mutations.
Lead Product(s): Exaluren Sulfate,Ivacaftor
Therapeutic Area: Genetic Disease Brand Name: ELX-02
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2023
Lead Product(s) : Exaluren Sulfate,Ivacaftor
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ELX-02 exaluren) is a small molecule drug candidate designed to restore production of full-length functional proteins. It is being developed for the treatment of CF patients with nonsense mutations.
Brand Name : ELX-02
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 14, 2023
Details:
ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. It is being developed for the treatment of CF patients with nonsense mutations.
Lead Product(s): ELX-02
Therapeutic Area: Genetic Disease Brand Name: ELX-02
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2023
Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. It is being developed for the treatment of CF patients with nonsense mutations.
Brand Name : ELX-02
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 24, 2023
Details:
ZKN-013 is a TURBO-ZM™ technology based molecule which allows rapid synthesis of novel oral ribosome modulating agents and has potential to fully unlock macrolide activity. It is being developed for recessive dystrophic epidermolysis bullosa with nonsense mutations.
Lead Product(s): ZKN-013
Therapeutic Area: Genetic Disease Brand Name: ZKN-013
Study Phase: IND EnablingProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2023
Lead Product(s) : ZKN-013
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Eloxx Pharmaceuticals Announces FDA Clearance to Begin Single Ascending Dose Study of ZKN-013
Details : ZKN-013 is a TURBO-ZM™ technology based molecule which allows rapid synthesis of novel oral ribosome modulating agents and has potential to fully unlock macrolide activity. It is being developed for recessive dystrophic epidermolysis bullosa with nonse...
Brand Name : ZKN-013
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 02, 2023
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?